<?xml version="1.0" encoding="UTF-8"?>
<p id="par0100">The COVID-19 outbreak has emphasized the urgent need to identify antiviral agents immediately available to combat SARS-CoV-2 infection. As shown in 
 <xref rid="tbl0005" ref-type="table">Table 1</xref> , among the many trials authorized all over the world to test the possible effectiveness of different drug candidates, almost 50 trials, to the best of our knowledge, imply the use of either IFN-α, or IFN-β at different dosages and by different delivery routes, alone as well as in combination with other drugs [
 <xref rid="bib0010" ref-type="bibr">2</xref>]. While such a complex scenario testifies the current interest in the potential use of IFN-I against COVID-19 pandemic [
 <xref rid="bib0310" ref-type="bibr">62</xref>], it also gives evidence of the lack of consensus on the best formulation, dose and delivery route for these cytokines.
</p>
